წყაროები
ძირითადი სტატიები
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloproliferative neoplasms [internet publication].სრული ტექსტი
Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 Apr;99(4):697-718.სრული ტექსტი აბსტრაქტი
Harrison CN, Butt N, Campbell P, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol. 2014 Nov;167(3):421-3. აბსტრაქტი
Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v85-99.სრული ტექსტი აბსტრაქტი
Harrison CN, Bareford D, Butt N, et al; British Committee for Standards in Haematology. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010 May;149(3):352-75.სრული ტექსტი აბსტრაქტი
გამოყენებული სტატიები
1. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-28.სრული ტექსტი აბსტრაქტი
2. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703-19.სრული ტექსტი აბსტრაქტი
3. Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990 Aug 1;66(3):549-56.სრული ტექსტი აბსტრაქტი
4. Bentley MA, Taylor KM, Wright SJ. Essential thrombocythaemia. Med J Aust. 1999 Aug 16;171(4):210-3. აბსტრაქტი
5. Michiels JJ, van Genderen PJ, Jansen PH, et al. Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leuk Lymphoma. 1996 Sep;22(suppl 1):65-70. აბსტრაქტი
6. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005 Feb;128(3):275-90.სრული ტექსტი აბსტრაქტი
7. Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019 Jun 11;3(11):1729-37.სრული ტექსტი აბსტრაქტი
8. Andriani A, Latagliata R, Anaclerico B, et al. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1,297 patients. Am J Hematol. 2016 Mar;91(3):318-21. აბსტრაქტი
9. Accurso V, Santoro M, Raso S, et al. Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: a single center study. Hematol Rep. 2019 Nov 29;11(4):8281.სრული ტექსტი აბსტრაქტი
10. Gangat N, Tefferi A. Myeloproliferative neoplasms and pregnancy: overview and practice recommendations. Am J Hematol. 2021 Mar 1;96(3):354-66.სრული ტექსტი აბსტრაქტი
11. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol. 2001 Mar;66(3):152-9. აბსტრაქტი
12. Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.სრული ტექსტი აბსტრაქტი
13. The Haematological Malignancy Research Network. Factsheets: essential thrombocythaemia 2022. Apr 2024 [internet publication].სრული ტექსტი
14. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006 Apr;32(3):171-3. აბსტრაქტი
15. Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600. აბსტრაქტი
16. Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008 May;83(5):359-62.სრული ტექსტი აბსტრაქტი
17. Brière JB. Essential thrombocythemia. Orphanet J Rare Dis. 2007 Jan 8;2:3.სრული ტექსტი აბსტრაქტი
18. Cross NCP, Godfrey AL, Cargo C, et al. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders. Br J Haematol. 2021 Nov;195(3):338-51.სრული ტექსტი აბსტრაქტი
19. Kang MG, Choi HW, Lee JH, et al. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget. 2016 Aug 30;7(35):57036-49.სრული ტექსტი აბსტრაქტი
20. Jang MA, Seo MY, Choi KJ, et al. A rare case of essential thrombocythemia with coexisting JAK2 and MPL driver mutations. J Korean Med Sci. 2020 Jun 15;35(23):e168.სრული ტექსტი აბსტრაქტი
21. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene. Blood. 1998 Aug 15;92(4):1091-6. აბსტრაქტი
22. Trifa AP, Cucuianu A, Popp RA. Familial essential thrombocythemia associated with MPL W515L mutation in father and JAK2 V617F mutation in daughter. Case Rep Hematol. 2014;2014:841787.სრული ტექსტი აბსტრაქტი
23. Accurso V, Santoro M, Mancuso S, et al. Familial essential thrombocythemia: 6 cases from a mono-institutional series. Clin Case Rep. 2022 Mar;10(3):e05525.სრული ტექსტი აბსტრაქტი
24. Allahverdi N, Yassin M, Ibrahim M. Environmental factors, lifestyle risk factors, and host characteristics associated with philadelphia negative myeloproliferative neoplasm: a systematic review. Cancer Control. 2021 Jan-Dec;28:10732748211046802.სრული ტექსტი აბსტრაქტი
25. Wiestner A, Schlemper RJ, van der Maas AP, et al. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998 Jan;18(1):49-52. აბსტრაქტი
26. Lussana F, Caberlon S, Pagani C, et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009 Sep;124(4):409-17. აბსტრაქტი
27. Finazzi G, Rambaldi A, Guerini V, et al. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007 Jan;92(1):135-6. აბსტრაქტი
28. De Stefano V, Za T, Rossi E, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009 May;94(5):733-7. აბსტრაქტი
29. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006 Feb;91(2):169-75. აბსტრაქტი
30. Marchetti M, Castoldi E, Spronk HM, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008 Nov 15;112(10):4061-8.სრული ტექსტი აბსტრაქტი
31. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005 Dec 3;366(9501):1945-53. აბსტრაქტი
32. van Genderen PJ, Budde U, Michiels JJ, et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol. 1996 Jun;93(4):962-5. აბსტრაქტი
33. Bucalossi A, Marotta G, Bigazzi C, et al. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol. 1996 May;52(1):14-20.სრული ტექსტი აბსტრაქტი
34. Accurso V, Santoro M, Mancuso S, et al. The essential thrombocythemia in 2020: what we know and where we still have to dig deep. Clin Med Insights Blood Disord. 2020 Dec 28;13:2634853520978210.სრული ტექსტი აბსტრაქტი
35. Tefferi A, Ho TC, Ahmann GJ, et al. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med. 1994 Oct;97(4):374-8. აბსტრაქტი
36. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008 Jan 1;111(1):60-70.სრული ტექსტი აბსტრაქტი
37. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloproliferative neoplasms [internet publication].სრული ტექსტი
38. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 Apr;99(4):697-718.სრული ტექსტი აბსტრაქტი
39. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014 Mar 6;123(10):1544-51.სრული ტექსტი აბსტრაქტი
40. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006 Dec 7;355(23):2452-66. აბსტრაქტი
41. Harrison CN, Butt N, Campbell P, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol. 2014 Nov;167(3):421-3. აბსტრაქტი
42. Haider M, Gangat N, Lasho T, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016 Jun;91(4):390-4.სრული ტექსტი აბსტრაქტი
43. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015 Nov 27;5(11):e369.სრული ტექსტი აბსტრაქტი
44. Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v85-99.სრული ტექსტი აბსტრაქტი
45. Harrison CN, Bareford D, Butt N, et al; British Committee for Standards in Haematology. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010 May;149(3):352-75.სრული ტექსტი აბსტრაქტი
46. Rocca B, Tosetto A, Betti S, et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood. 2020 Jul 9;136(2):171-82.სრული ტექსტი აბსტრაქტი
47. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May;32(5):1057-69.სრული ტექსტი აბსტრაქტი
48. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.სრული ტექსტი აბსტრაქტი
49. Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011 Jun 10;29(17):2410-5.სრული ტექსტი აბსტრაქტი
50. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013 Aug 8;122(6):893-901.სრული ტექსტი აბსტრაქტი
51. Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015 Dec 10;126(24):2585-91.სრული ტექსტი აბსტრაქტი
52. Rumi E, Cazzola M. How I treat essential thrombocythemia. Blood. 2016 Nov 17;128(20):2403-14.სრული ტექსტი აბსტრაქტი
53. Shvidel L, Sigler E, Haran M, et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia. 2007 Sep;21(9):2071-2. აბსტრაქტი
54. Finazzi G, Ruggeri M, Rodeghiero F, et al. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000 Sep;110(3):577-83.სრული ტექსტი აბსტრაქტი
55. Tefferi A, Szuber N, Vallapureddy RR, et al. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. Am J Hematol. 2019 Jan;94(1):5-9.სრული ტექსტი აბსტრაქტი
56. Bieniaszewska M, Sobieralski P, Leszczyńska A, et al. Anagrelide in essential thrombocythemia: efficacy and long-term consequences in young patient population. Leuk Res. 2022 Dec;123:106962.სრული ტექსტი აბსტრაქტი
57. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009 May 14;113(20):4829-33.სრული ტექსტი აბსტრაქტი
58. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special Issue. J Clin Apher. 2019 Jun;34(3):171-354. აბსტრაქტი
59. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. Haematologica. 2004 Feb;89(2):215-32. აბსტრაქტი
60. Passamonti F, Rumi E, Randi ML, et al. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. J Thromb Haemost. 2010 Feb;8(2):411-3.სრული ტექსტი აბსტრაქტი
61. Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019 Oct 2;2(10):e1912666.სრული ტექსტი აბსტრაქტი
62. Bates SM, Middeldorp S, Rodger M, et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016 Jan;41(1):92-128.სრული ტექსტი აბსტრაქტი
63. Ruggeri M, Rodeghiero F, Tosetto A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008 Jan 15;111(2):666-71.სრული ტექსტი აბსტრაქტი
64. Beer PA, Erber WN, Campbell PJ, et al. How I treat essential thrombocythemia. Blood. 2011 Feb 3;117(5):1472-82.სრული ტექსტი აბსტრაქტი
65. Gunawan A, Harrington P, Garcia-Curto N, et al. Ruxolitinib for the treatment of essential thrombocythemia. Hemasphere. 2018 Aug;2(4):e56.სრული ტექსტი აბსტრაქტი
66. Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017 Oct 26;130(17):1889-97.სრული ტექსტი აბსტრაქტი
67. Alvarez-Larrán A, Sant'Antonio E, Harrison C, et al. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematol. 2021 Sep;8(9):e658-e665. აბსტრაქტი
68. Szuber N, Vallapureddy RR, Penna D, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018 Dec;93(12):1474-84.სრული ტექსტი აბსტრაქტი
69. Smith CJ, Thomas JW, Ruan G, et al. A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: comparison with data from a Mayo Clinic single institutional series. Am J Hematol. 2021 Dec 1;96(12):E464-8.სრული ტექსტი
70. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011 Aug 10;29(23):3179-84. აბსტრაქტი
71. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015 Nov 13;5:e366.სრული ტექსტი აბსტრაქტი
72. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004 Nov 15;117(10):755-61. აბსტრაქტი
73. Griesshammer M, Heimpel H, Pearson TC. Essential thrombocythemia and pregnancy. Leuk Lymphoma. 1996 Sep;22(suppl 1):57-63. აბსტრაქტი
ამ მასალის გამოყენება ექვემდებარება ჩვენს განცხადებას